Impaired vasodilatation response to amrinone in the forearm of patients with congestive heart failure: role of endothelium-derived nitric oxide.

Abstract:

:Recent in vitro experiments have shown that amrinone enhances the release of nitric oxide (NO) from the endothelium and induces NO mediated vasodilatation. This in vivo study examined whether amrinone causes vasodilatation mediated by endothelium-derived NO, and whether this effect is attenuated in patients with endothelial dysfunction. Eight patients with congestive heart failure and 10 age- and sex-matched healthy volunteers were studied. Forearm blood flow (FBF) was measured before and during infusion of drugs of acetylcholine, amrinone, and nitroglycerin in incremental doses. After the completion of these measurements, 100 micromol of N(G)-monomethyl-L-arginine (L-NMMA) was infused intraarterially. Thereafter, FBF measurement in response to incremental doses of amrinone was repeated. Infusion of incremental doses of amrinone caused a comparable increase in amrinone plasma concentration in both groups. Baseline FBF was 3.2+/-0.79 ml/min/100 ml in controls vs. 2.91+/-0.79 ml/min/100 ml in patients (p = 0.43). In both groups, FBF increased in response to acetylcholine, amrinone, and nitroglycerin. During infusion of the highest dose of nitroglycerin, FBF was not different between the two groups (p = 0.51); however, FBF during infusion of the highest doses of acetylcholine and amrinone was significantly less in patients than in controls: 9.75+/-2.69 vs. 24.87+/-8.65 ml/min/100 ml (p < 0.001) and 3.79+/-1.21 vs. 7.15+/-2.06 ml/min/100 ml (p < 0.001), respectively. L-NMMA significantly depressed the increase in FBF in response to amrinone in controls, but not in patients. In conclusion, the selective PDE III inhibitor, amrinone, has endothelium-derived NO-mediated vasodilating effects in addition to direct effects. This property may be impaired in patients with endothelial dysfunction.

journal_name

J Cardiovasc Pharmacol

authors

Sakane T,Ishibashi Y,Shimada T,Takahashi N,Sugamori T,Hirano Y,Ohata S,Inoue SI,Nakamura K,Murakami Y

doi

10.1097/00005344-200008000-00008

subject

Has Abstract

pub_date

2000-08-01 00:00:00

pages

188-95

issue

2

eissn

0160-2446

issn

1533-4023

journal_volume

36

pub_type

临床试验,杂志文章
  • Antiarrhythmic Effect of Either Negative Modulation or Blockade of Small Conductance Ca2+-activated K+ Channels on Ventricular Fibrillation in Guinea Pig Langendorff-perfused Heart.

    abstract::During recent years, small conductance Ca-activated K (SK) channels have been reported to play a role in cardiac electrophysiology. SK channels seem to be expressed in atria and ventricles, but from a functional perspective, atrial activity is predominant. A general notion seems to be that cardiac SK channels are pred...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000278

    authors: Diness JG,Kirchhoff JE,Sheykhzade M,Jespersen T,Grunnet M

    更新日期:2015-09-01 00:00:00

  • Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells.

    abstract::Exposure of endothelial cells (ECs) to thrombin or cytokines leads to major changes in their biochemical properties, which confer procoagulant activities. Stimulated ECs express the procoagulant glycoprotein tissue factor (TF). Although some TF is expressed on the apical surface of the cells, most is deposited as a cr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199500252-00019

    authors: Leclerc NE,Haan-Archipoff G,Lenoble M,Beretz A

    更新日期:1995-01-01 00:00:00

  • Anakinra in Recurrent Pericarditis: Current Evidence on Clinical Use, Effectiveness, and Safety.

    abstract::Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0000000000000839

    authors: Correia ETO,Dos Santos Barbetta LM,de Almeida JPCL,Mesquita ET

    更新日期:2020-07-01 00:00:00

  • Apigenin Prevent Abdominal Aortic Aneurysms Formation by Inhibiting the NF-κB Signaling Pathway.

    abstract::Abdominal aortic aneurysms (AAA) is a multifactorial vascular disease with a high rate of mortality and brings heavy burden to both human and society. The pathological process behind AAA is complex. Elastin degradation, chronic inflammation, and vascular smooth muscle cell phenotypic modulation are involved in AAA for...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000785

    authors: Li D,Ma J,Wang L,Xin S

    更新日期:2020-03-01 00:00:00

  • Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.

    abstract::CGS 26303 has previously been shown to inhibit human endothelin converting enzyme-1 (ECE-1) with an IC50 of 410 nM and to be efficacious in several animal disease models. However, it is a more potent inhibitor of neutral endopeptidase 24.11 (NEP) with an IC50 of 1 nM. The aim of this study was to optimize CGS 26303 fo...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200036051-00014

    authors: Jeng AY,De Lombaert S,Beil ME,Bruseo CW,Savage P,Chou M,Trapani AJ

    更新日期:2000-11-01 00:00:00

  • Depressor effect of intrathecal neuropeptide Y (NPY) Is mediated by Y2 subtype of NPY receptors.

    abstract::The effect of intrathecal administration of neuropeptide Y (NPY), NPY COOH-terminal fragments as well as an NPY Y1 receptor ligand on arterial blood pressure (ABP) of anesthetized rat was studied. NPY and all NPY COOH-terminal fragments tested (NPY11-36, NPY14-36 and NPY18-36), believed to act through Y2 receptors pro...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199305000-00005

    authors: Chen X,Westfall TC

    更新日期:1993-05-01 00:00:00

  • Effects of the aminopeptidase P inhibitor apstatin on bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes.

    abstract::We investigated the effect of apstatin (an aminopeptidase P inhibitor) on bradykinin-induced inositol 1,4,5-triphosphate (IP3) formation and glucose uptake in isolated neonatal rat cardiomyocytes. Apstatin enhanced bradykinin-induced IP3 formation in a dose-dependent manner. We found that 1 microM Hoe 140 (a bradykini...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200105000-00001

    authors: Kudoh A,Kudoh E,Katagai H,Takazawa T

    更新日期:2001-05-01 00:00:00

  • Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction.

    abstract::Ranolazine was previously shown to stimulate cardiac glucose oxidation. Dichloroacetate (DCA) also does and was shown to improve exercise capacity in animals, but it has long-term toxicity problems. To test the hypothesis that ranolazine would increase exercise performance in the chronic heart failure (CHF) condition,...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199609000-00002

    authors: Aaker A,McCormack JG,Hirai T,Musch TI

    更新日期:1996-09-01 00:00:00

  • Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.

    abstract:BACKGROUND:Factor Xa (FXa) has been a target of considerable interest for drug development efforts aimed at suppressing thrombosis. In this report, a new orally active, small molecule, active-site directed FXa inhibitor, GW813893, has been profiled in a succession of in vitro and in vivo assays involved in its preclini...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e31817e9b9e

    authors: Abboud MA,Needle SJ,Burns-Kurtis CL,Valocik RE,Koster PF,Amour AJ,Chan C,Brown D,Chaudry L,Zhou P,Patikis A,Patel C,Pateman AJ,Young RJ,Watson NS,Toomey JR

    更新日期:2008-07-01 00:00:00

  • Receptors for endothelin in the central nervous system.

    abstract::The quantitative receptor autoradiographic method we used revealed that specific [125I]endothelin-1 ([125I]ET-1) binding sites are highly concentrated in the choroid plexus (ChP), subfornical organ (SFO), lacunosum molecular layer of the hippocampus (LMol), and granular layer of the cerebellum (GC) of the rat brain. [...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199100177-00037

    authors: Niwa M,Kawaguchi T,Fujimoto M,Kataoka Y,Taniyama K

    更新日期:1991-01-01 00:00:00

  • Protein Kinase C Isoforms Distinctly Regulate Propofol-induced Endothelium-dependent and Endothelium-independent Vasodilation.

    abstract::Protein kinase C (PKC) isoforms improve endothelial nitric oxide synthase activity and contractile Ca sensitivity in blood vessels. These actions may have opposite effects on propofol-induced vasodilation. This study examines the hypothesis that propofol induces relaxation by enhancing the PKC-mediated nitric oxide sy...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000275

    authors: Wang Y,Zhou H,Wu B,Zhou Q,Cui D,Wang L

    更新日期:2015-09-01 00:00:00

  • Effects of the converting enzyme inhibitor quinapril (CI-906) on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension.

    abstract::Fourteen patients with mild to moderate essential hypertension were randomized, after a baseline placebo period of 4 weeks, to receive the angiotensin converting enzyme (ACE) inhibitor quinapril or a placebo. During a 12 week, double-blind phase, the dosage of quinapril was increased from 10 to 40 mg twice daily being...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-198807000-00012

    authors: Säynävälammi P,Pörsti I,Pörsti P,Nurmi AK,Seppälä E,Manninen V,Vapaatalo H

    更新日期:1988-07-01 00:00:00

  • 17-Beta estradiol regulation of myocardial glutathione and its role in protection against myocardial stunning in dogs.

    abstract::We studied the effect of 2-week treatment with estradiol 17beta on myocardial glutathione concentration in dogs and isolated perfused rat heart subjected to brief coronary ischemia and reperfusion. Estradiol protected against ischemia/reperfusion-induced myocardial systolic shortening and malonylaldehyde production an...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199809000-00017

    authors: Kim YD,Farhat MY,Myers AK,Kouretas P,DeGroot KW,Pacquing A,Ramwell PW,Suyderhoud JP,Lees DE

    更新日期:1998-09-01 00:00:00

  • Changes in the pathophysiologic profile of blood pressure determinants during short-term enalapril administration.

    abstract::To assess dose-related effects of enalapril, we treated eight hospitalized hypertensive patients receiving constant sodium intake with incremental doses of this new angiotensin converting-enzyme blocking drug. After a few days of placebo treatment, enalapril was given in single daily doses, starting with 1.25 mg and i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198600081-00006

    authors: de Leeuw PW,Birkenhäger WH

    更新日期:1986-01-01 00:00:00

  • Racial differences in beta-adrenoceptor-mediated responsiveness.

    abstract::Previous studies have suggested that racial differences may exist in beta-adrenoceptor-mediated responsiveness. However, no clear conclusions can be drawn based on these studies because of the confounding effect of the parasympathetic nervous system on responses to isoproterenol bolus doses. In this study, we blocked ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00005344-199501000-00015

    authors: Johnson JA,Burlew BS,Stiles RN

    更新日期:1995-01-01 00:00:00

  • Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction.

    abstract::This study investigated the effects of adrenomedullin on left ventricular myocardial contraction and relaxation, coronary blood flow, and myocardial oxygen consumption in comparison with those of atrial natriuretic peptide (ANP). Fourteen patients who had had myocardial infarctions were randomly assigned to receive IV...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-200205000-00017

    authors: Nagaya N,Goto Y,Satoh T,Sumida H,Kojima S,Miyatake K,Kangawa K

    更新日期:2002-05-01 00:00:00

  • Drug interactions: the new phosphodiesterase inhibitor enoximone and the calcium channel blocker nifedipine in coronary surgery patients--influence on hemodynamics and plasma concentrations.

    abstract::The calcium channel blocker nifedipine and the new phosphodiesterase (PDE) inhibitor enoximone are used in the treatment of cardiovascular diseases. Since both substances are acting on slow calcium channels and because systemic elimination of these two agents is dependent on oxidative drug metabolizing enzyme activity...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Boldt J,Kling D,Dietevich HA,Hempelmann G

    更新日期:1990-01-01 00:00:00

  • Hemodynamic response to adenosine infusion before and after coronary artery bypass surgery.

    abstract::This study describes the hemodynamic dose-response characteristics of a titrated, continuous adenosine infusion before and 1 h (anesthetized), 1 week, and 1 year after coronary artery bypass graft (CABG) surgery. Average tolerated adenosine infusion rates were less 1 h and 1 week after surgery (128 +/- 23 and 118 +/- ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199703000-00005

    authors: Anderson RE,Lind B,Owall A,Brodin LA

    更新日期:1997-03-01 00:00:00

  • Pulmonary vascular and airway responses to systemic vasoconstrictors in anesthetized BALB/c mice.

    abstract::There is no systematic study in which the effects of vasoactive substances were investigated on pulmonary vascular resistance (PVR) in in vivo mouse by directly measuring cardiac output and the inflow and outflow pressures in the pulmonary circulation. We determined the responses of PVR, total peripheral resistance (T...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000199

    authors: Wang M,Shibamoto T,Shinomiya S,Yamamoto Y,Kurata Y,Kuda Y,Tanida M,Toga H

    更新日期:2015-04-01 00:00:00

  • Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes.

    abstract::Calcium sensitizers increase myocardial contractile function without affecting Ca2+ homeostasis, which might be beneficial in the treatment of patients with heart failure. However, it remains uncertain whether Ca sensitizers induce quantitatively similar inotropic responses in control and failing hearts. To compare th...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200101000-00003

    authors: Tsutsui H,Kinugawa S,Ide T,Hayashidani S,Suematsu N,Satoh S,Nakamura R,Egashira K,Takeshita A

    更新日期:2001-01-01 00:00:00

  • Pentoxifylline Ameliorates Cardiac Fibrosis, Pathological Hypertrophy, and Cardiac Dysfunction in Angiotensin II-induced Hypertensive Rats.

    abstract::Inflammation induces cardiac fibrosis and hypertrophy in multiple cardiovascular diseases, contributing to cardiac dysfunction. We tested the hypothesis that pentoxifylline (PTX), a phosphodiesterase inhibitor with anti-inflammatory property, would attenuate cardiac fibrosis and hypertrophy, and prevent cardiac dysfun...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000316

    authors: Zhang X,Meng F,Song J,Zhang L,Wang J,Li D,Li L,Dong P,Yang B,Chen Y

    更新日期:2016-01-01 00:00:00

  • Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations.

    abstract::MCI-154 is a potent nonglycoside and non-sympathomimetic cardiotonic agent with a pyridazinone structure. We assessed its cardiac and coronary vasodilator effects by use of isolated, blood-perfused papillary muscle, sinoatrial (SA) node, and atrioventricular (AV) node preparations of dogs. The drug (1-100 nmol) was in...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198712000-00013

    authors: Hosono M,Taira N

    更新日期:1987-12-01 00:00:00

  • C-phycocyanin ameliorates doxorubicin-induced oxidative stress and apoptosis in adult rat cardiomyocytes.

    abstract::Doxorubicin (DOX), a potent antineoplastic agent, poses limitations for its therapeutic use due to the associated risk of developing cardiomyopathy and congestive heart failure. The cardiotoxicity of doxorubicin is associated with oxidative stress and apoptosis. We have recently shown that Spirulina, a blue-green alga...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/01.fjc.0000191520.48404.27

    authors: Khan M,Varadharaj S,Shobha JC,Naidu MU,Parinandi NL,Kutala VK,Kuppusamy P

    更新日期:2006-01-01 00:00:00

  • Time course of spirapril-induced structural and functional changes after myocardial infarction in rats followed with magnetic resonance imaging.

    abstract::Structural alterations after myocardial infarction (MI) in rats are usually examined only after death of the experimental animal. Magnetic resonance imaging (MRI) allows repeated and noninvasive measurements of important structural [left ventricular (LV) mass, LV wall thickness, LV chamber radius] as well as function ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199306000-00014

    authors: Zierhut W,Rudin M,Robertson E,Zerwes HG,Novosel D,Evenou JP,Stirnimann R,Hof RP

    更新日期:1993-06-01 00:00:00

  • Amiodarone pretreatment effects on ischemic isovolumic rat hearts: a P-31 nuclear magnetic resonance study of intracellular pH and high-energy phosphates contents evolutions.

    abstract::Effects of amiodarone injected intravenously (i.v.) at two doses (10 and 20 mg/kg) on perfused isovolumic rat hearts were assessed by P-31 nuclear magnetic resonance (NMR). P-31 NMR is used to measure intracellular myocardial pH, phosphocreatine (PCr), and ATP contents time evolutions. Myocardial mechanical function i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Vander Elst L,Goudemant JF,Mouton J,Chatelain P,Van Haverbeke Y,Muller RN

    更新日期:1990-03-01 00:00:00

  • The role of endothelin in mediating ischemia/hypoxia-induced atrial natriuretic peptide release.

    abstract::The aim of the present study was to investigate the putative role of endothelin (ET) in mediating ischemia/hypoxia-induced ANP release utilizing exogenous ET-1 or ET receptor antagonists (BQ-123 or Bosentan). Isolated rat hearts with non-distended atria were perfused using a Langendorff apparatus and heart rate mainta...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200402000-00010

    authors: Zhang Y,Oliver JR,Horowitz JD

    更新日期:2004-02-01 00:00:00

  • Endothelial function, nitric oxide, and cocoa flavanols.

    abstract::Endothelial dysfunction is the pathophysiologic principle involved in the initiation and progression of arteriosclerosis, thus endothelial function serves as a "barometer" for cardiovascular health that can be used for the evaluation of new therapeutic strategies. This review provides an introduction to the concept of...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-200606001-00007

    authors: Heiss C,Schroeter H,Balzer J,Kleinbongard P,Matern S,Sies H,Kelm M

    更新日期:2006-01-01 00:00:00

  • Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cyclic AMP accumulation.

    abstract::Angiopeptin (AP: BIM23014C), a cyclic analogue of the peptide hormone somatostatin, inhibits intimal hyperplasia after balloon angioplasty. This inhibition has been attributed to a direct inhibitory effect on smooth muscle cell (SMC) proliferation. However, the SMC that proliferate in the intima and contribute to inti...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199504000-00015

    authors: Mooradian DL,Fernandes B,Diglio CA,Lester BR

    更新日期:1995-04-01 00:00:00

  • Effects of endothelin-induced nitric oxide on venous circulation and renal water-electrolyte handling.

    abstract::To assess the interaction of endothelin (ET) with nitric oxide (NO) and the effects on venous circulation and handling of renal water and electrolytes, ET (1.0 ng/kg/min) or saline was administered with or without three doses (0.27, 2.7 and 27 ng/kg/min for 40 min) of N omega-nitro-L-arginine methyl ester (L-NAME), an...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199800001-00039

    authors: Ota K,Kimura T,Shoji M,Ota M,Funyu T,Mori T,Sahata T

    更新日期:1998-01-01 00:00:00

  • The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.

    abstract::This open, general practice study looked at the pharmacokinetics of ramipril over a period of 1 year in elderly (greater than 65 years) hypertensive patients. Ten patients with a diastolic blood pressure between 95 and 125 mm Hg were treated with 5 mg of ramipril daily for 4 weeks, followed by an additional 11 months ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Hosie J,Meredith P

    更新日期:1991-01-01 00:00:00